DNA methylation, catalyzed by DNMT enzymes, is a central epigenetic mechanism frequently disrupted in cancer, where aberrant hypermethylation contributes to tumor suppressor gene silencing. Researchers from Nankai University reported the discovery and preclinical characterization of [I], a selective DNMT1 degrader in models of acute myeloid leukemia (AML).

The MTHFD enzyme family is central to one-carbon metabolism, with MTHFD2 showing cancer-selective overexpression linked to poor prognosis. Emerging data also identify MTHFD1 as a therapeutic vulnerability in select tumors, supporting MTHFD-targeted drug development.

More effective treatments are needed for patients with myelodysplastic syndrome (MDS), a heterogeneous group of myeloid disorders that frequently progress to acute myeloid leukemia (AML). In a recent publication, Debiopharm SA and The Ohio State University demonstrate that MDS cells express CD37 and that both AML and MDS cells exhibit efficient internalization of this receptor. Debio-1562M, under development at Debiopharm, is a next-generation antibody-drug conjugate (ADC) targeting CD37.

Delta-Fly Pharma Inc. is pressing ahead with discussions with the FDA for its lead acute myeloid leukemia (AML) candidate, radgocitabine (DFP-10917), despite a phase III miss on its primary endpoint, instead leaning on earlier-stage efficacy signals and emerging combination data to support a potential path toward conditional approval.

Delta-Fly Pharma Inc. is pressing ahead with discussions with the FDA for its lead acute myeloid leukemia (AML) candidate, radgocitabine (DFP-10917), despite a phase III miss on its primary endpoint, instead leaning on earlier-stage efficacy signals and emerging combination data to support a potential path toward conditional approval.

Mabwell (Shanghai) Bioscience Co. Ltd.’s has announced IND acceptance by China’s National Medical Products Administration (NMPA) for the company’s LILRB4/CD3 T-cell engager bispecific antibody 6MW5311. The drug candidate is being developed for hematologic malignancies, specifically acute myeloid leukemia (AML), chronic myelomonocytic leukemia and multiple myeloma.

KMT2A-rearranged acute myeloid leukemia (AML) is a highly aggressive leukemia subtype characterized by poor prognosis and high relapse rates. Because the menin-MLL interaction is essential for the stability and transcriptional activity of MLL fusion complexes, targeting this protein-protein interaction represents a promising therapeutic strategy for this aggressive form of AML. Researchers from Zhejiang University reported the discovery and preclinical characterization of [I], a novel menin inhibitor, designed for the treatment of AML.

Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and inflammation, then, may hold the keys to preventing blood cancers, according to John E. Dick’s plenary session at the 2026 Korean Society of Hematology International Conference, held March 26, 2026.

Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and inflammation, then, may hold the keys to preventing blood cancers, according to John E. Dick’s plenary session at the 2026 Korean Society of Hematology International Conference, held March 26, 2026.